Dublin, Ireland, 3rd July, 2012 – ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced appointments to the senior management teams of its Clinical and Central Laboratories businesses.
Dr. Nuala Murphy has been appointed Executive Vice President, Global Clinical Operations and Data Management, while Dr. Mark Roseman has joined ICON as Executive Vice President, Global Scientific Operations. Dr. Era Khurana has joined ICON’s Central Laboratories’ leadership team as Medical Director.
• Dr. Nuala Murphy. Dr. Nuala Murphy has over 20 years’ experience within the pharmaceutical and CRO industries. She joins ICON from Quintiles, where she managed clinical research professionals in Europe and Africa in her role as Vice President, Clinical Operations. Dr. Murphy also has over a decade of experience in therapeutics having led the CNS and internal medicine project management divisions for Quintiles. Nuala holds a Bachelor of Science degree in Biochemistry from Trinity College Dublin, a PhD in Neurochemistry from the University of Leeds and conducted post-doctoral research in Neuropharmacology at the Collège de France in Paris.
• Dr. Mark Roseman joins ICON with over 25 years of clinical research experience. Prior to ICON, he was Executive Vice President of Business Development at Kendle/INC. Dr. Roseman also held senior management positions in both operations and business development at PPD and supervised the oncology, cardiovascular, anti-infective, and respiratory therapeutic areas. Prior to this, Dr. Roseman supervised all data management, clinical operations, biostatistics, and medical writing activities at CIBA Vision and was responsible for the conduct of their registration trials. Dr. Roseman earned his Master of Public Health and Doctor of Science degrees in Epidemiology from Boston University.
• Dr. Era Khurana joins ICON as Medical Director, ICON Central Laboratories. Dr Khurana will provide scientific leadership and guidance and drive standards of performance and quality at ICON’s laboratories in Farmingdale, New York; Dublin, Ireland; Bangalore, India and Singapore. Dr. Khurana has over 28 years of pathology experience and joins ICON from Quest Diagnostics Inc., where she was Director of Anatomical and Clinical Pathology. Prior to this, Dr. Khurana served as Chief of Surgical Pathology at South Nassau Community Hospital, New York. Dr. Khurana holds a Doctor of Medicine degree from Dayanand Medical College in India and received her Medical Licensure from the New York State Board.
Commenting on the appointments, Ciaran Murray, CEO at ICON plc, said: “I’m delighted to welcome Nuala, Mark and Era to the team at ICON. All three bring a wealth of operational, medical and therapeutic experience to ICON which we will leverage to support the design, planning and delivery of our clients’ drug development programmes.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 8,800 employees, operating from 84 locations in 40 countries.
Further information is available at www.iconplc.com